0.67 USD
▼-0.02-3.23%
盘后 0.69 +3.00%
2026-09-15
市值
$147.48M
市盈率
—
EPS
-0.53
股息率
—
52 周区间
0.53 – 2.35
成交量
1.84M
Beta
2.78
目标价
3.20
52W 低 0.5352W 高 2.35
价格走势
公司简介
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ...